ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the United States District Court for the District of Delaware granted Amgen's (Nasdaq: AMGN) motion for summary judgment of non-infringement of seven claims of U.S. Patent No. 6,410,516 (the '516 patent) based on activities related to Enbrel(R) (etanercept). The court found that administration of Enbrel falls outside the scope of the asserted claims based on the court's interpretation of these claims to exclude extracellular methods of reducing NF-(kappa)B activity.
The details can be read here.
No comments:
Post a Comment